Search Results - "PHAN, Alexandria T"

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors by Caplin, Martyn E, Pavel, Marianne, Ćwikła, Jarosław B, Phan, Alexandria T, Raderer, Markus, Sedláčková, Eva, Cadiot, Guillaume, Wolin, Edward M, Capdevila, Jaume, Wall, Lucy, Rindi, Guido, Langley, Alison, Martinez, Séverine, Blumberg, Joëlle, Ruszniewski, Philippe

“…As compared with placebo, extended-release lanreotide (120 mg every 28 days) was associated with delayed disease progression in patients with nonfunctional,…”
Get full text

Reduction of Cancer-Related Fatigue With Dexamethasone: A Double-Blind, Randomized, Placebo-Controlled Trial in Patients With Advanced Cancer by YENNURAJALINGAM, Sriram, FRISBEE-HUME, Susan, DALAL, Shalini, MASSIE, Lisa, REDDY, Suresh K, BRUERA, Eduardo, LYNN PALMER, J, DELGADO-GUAY, Marvin O, BULL, Janet, PHAN, Alexandria T, TANNIR, Nizar M, KEATING LITTON, Jennifer, REDDY, Akhila, HUI, David

“…Cancer-related fatigue (CRF) is the most common symptom in patients with advanced cancer. The primary objective of this prospective, randomized, double-blind,…”
Get full text

Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study by YAO, James C, PHAN, Alexandria T, MERIC-BERNSTAM, Funda, CHANG, David Z, WOLFF, Robert A, HESS, Kenneth, GUPTA, Sanjay, JACOBS, Carmen, MARES, Jeannette E, LANDGRAF, Andrea N, RASHID, Asif

“…Evaluate the activity of everolimus (RAD001) in combination with octreotide long-acting repeatable (LAR) in patients with advanced low- to intermediate-grade…”
Get full text

The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas by Strosberg, Jonathan R, Coppola, Domenico, Klimstra, David S, Phan, Alexandria T, Kulke, Matthew H, Wiseman, Gregory A, Kvols, Larry K

“…Extrapulmonary poorly differentiated neuroendocrine carcinomas can originate in the gastrointestinal tract, bladder, cervix, and prostate. These high-grade…”
Get full text

Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study by Phan, Alexandria T, MD, Halperin, Daniel M, MD, Chan, Jennifer A, MD, Fogelman, David R, MD, Hess, Kenneth R, Prof, Malinowski, Paige, BA, Regan, Eileen, MSN, Ng, Chaan S, Prof, Yao, James C, Prof, Kulke, Matthew H, MD

“…Summary Background Treatment options for advanced, well-differentiated neuroendocrine tumours (NETs) remain scarce. Pazopanib is an orally bioavailable, small…”
Get full text

PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors by MERIC-BERNSTAM, Funda, AKCAKANAT, Argun, PHAN, Alexandria T, WOLFF, Robert A, GUPTA, Sanjay, MILLS, Gordon B, YAO, James, HUIQIN CHEN, DO, Kim-Anh, SANGAI, Takafumi, ADKINS, Farrell, GONZALEZ-ANGULO, Ana Maria, RASHID, Asif, CROSBY, Katherine, MEI DONG

“…We sought to determine whether phosphoinositide 3-kinase (PI3K) pathway mutation or activation state and rapamycin-induced feedback loop activation of Akt is…”
Get full text

Everolimus in Advanced Pancreatic Neuroendocrine Tumors: The Clinical Experience by YAO, James C, PHAN, Alexandria T, JEHL, Valentine, SHAH, Gaurav, MERIC-BERNSTAM, Funda

“…The incidence of neuroendocrine tumors (NET) has increased dramatically in the past 30 years. This information has revitalized basic and clinical research into…”
Get full text

Immunotherapy and targeted therapy-the new roadmap in cancer treatment by Shahid, Kamran, Khalife, Mustafa, Dabney, Raetasha, Phan, Alexandria T

“…Immunotherapy is the new frontier in cancer medicine. This manuscript summarizes historical aspect of immunotherapy, particularly its pathway to drug approval…”
Get full text

New Strategies for Advanced Neuroendocrine Tumors in the Era of Targeted Therapy by MEI DONG, PHAN, Alexandria T, YAO, James C

“…Low- to intermediate-grade neuroendocrine tumor (NET) constitutes a group of indolent malignancies that share the capacity for secreting hormones and…”
Get full text

Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well-differentiated neuroendocrine tumors by Yao, James C, Phan, Alexandria T, Hess, Kenneth, Fogelman, David, Jacobs, Carmen, Dagohoy, Cecile, Leary, Colleen, Xie, Keping, Ng, Chaan S

“…This study aimed to assess the antitumor activity of everolimus and bevacizumab among patients with advanced neuroendocrine tumors and to assess perfusion…”
Get full text

The FGFR4-G388R Single-Nucleotide Polymorphism Alters Pancreatic Neuroendocrine Tumor Progression and Response to mTOR Inhibition Therapy by SERRA, Stefano, LEI ZHENG, HASSAN, Manal, PHAN, Alexandria T, WOODHOUSE, Linda J, YAO, James C, EZZAT, Shereen, ASA, Sylvia L

“…Pancreatic neuroendocrine tumors (pNET), also known as islet cell tumors, exhibit a wide range of biologic behaviors ranging from long dormancy to rapid…”
Get full text

Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors by Wolin, Edward M., Manon, Amandine, Chassaing, Christophe, Lewis, Andy, Bertocchi, Laurent, Richard, Joel, Phan, Alexandria T.

“…Purpose Peptide drugs for antineoplastic therapies usually have low oral bioavailability and short in vivo half-lives, requiring less preferred delivery…”
Get full text

Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas by Crumley, Suzanne M, Pepper, Kristi L, Phan, Alexandria T, Olsen, Randall J, Schwartz, Mary R, Portier, Bryce P

“…-Colorectal carcinoma is the third most common cause of cancer death in males and females in the United States. Rectal adenocarcinoma can have distinct…”
Get full text

Treatment Patterns of Long-Acting Somatostatin Analogs for Neuroendocrine Tumors by Clarke, Callisia N, Cockrum, Paul, Beveridge, Thomas J R, Jerry, Michelle, McMorrow, Donna, Tran, Anh Thu, Phan, Alexandria T

“…Long-acting somatostatin analog therapy (LA-SSA) is recommended as first-line therapy for treatment of unresectable or metastatic neuroendocrine tumors (NETs)…”
Get full text

Clinical benefit of palliative radiation therapy in advanced gastric cancer by Kim, Michelle M, Rana, Vishal, Janjan, Nora A, Das, Prajnan, Phan, Alexandria T, Delclos, Marc E, Mansfield, Paul F, Ajani, Jaffer A, Crane, Christopher H, Krishnan, Sunil

“…Local progression of advanced gastric cancer often manifests as bleeding, dysphagia/obstruction, or pain. We evaluated the magnitude and durability of…”
Get more information

Adrenal Cortical Carcinoma—Review of Current Knowledge and Treatment Practices by Phan, Alexandria T., MD

“…Adrenal cortical carcinoma is a rare endocrine malignancy with a poor long-term prognosis. Accurate diagnosis and preoperative evaluation of the patient…”
Get full text

Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma by Gonzalez, Ricardo J., MD, Tamm, Eric P., MD, Ng, Chaan, MD, Phan, Alexandria T., MD, Vassilopoulou-Sellin, Rena, MD, Perrier, Nancy D., MD, Evans, Douglas B., MD, Lee, Jeffrey E., MD

“…Background Adrenal cortical carcinoma (ACC) is a rare disease in which recurrence after surgery is common. Mitotane is the primary systemic treatment for…”
Get full text

Multicenter Phase II Trial of S-1 Plus Cisplatin in Patients With Untreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma by AJANI, Jaffer A, LEE, Fa-Chyi, SINGH, Deepti A, HALLER, Daniel G, LENZ, Heinz-Josef, BENSON, Al B, YANAGIHARA, Ronald, PHAN, Alexandria T, YAO, James C, STRUMBERG, Dirk

“…S-1 plus cisplatin is considered highly active in Japanese gastric cancer patients. We conducted a phase II multi-institutional trial, in the West, in patients…”
Get full text

Neuroendocrine Tumors: a Relevant Clinical Update by Rizen, Emma N., Phan, Alexandria T.

“…Purpose of Review The field of neuroendocrine oncology has changed much since the time of Oberndorfer first described and coined the term carcinoid. The…”
Get full text

Impact of 18F-FDG PET/CT on the management of adrenocortical carcinoma: analysis of 106 patients by Takeuchi, Satoshi, Balachandran, Aparna, Habra, Mouhammed Amir, Phan, Alexandria T., Bassett, Roland L., Macapinlac, Homer A., Chuang, Hubert H.

“…Purpose Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy. Limited data are available about on value of 18 F-FDG PET/CT in ACC. We evaluated…”
Get full text